menu
    • menu
    [{"orgOrder":0,"company":"Abdi Ibrahim","sponsor":"Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AI201901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Abdi Ibrahim","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni","highestDevelopmentStatusID":"10","companyTruncated":"Abdi Ibrahim \/ Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni"},{"orgOrder":0,"company":"Abdi Ibrahim","sponsor":"Abdi Ibrahim","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EPs 7630","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abdi Ibrahim","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Abdi Ibrahim \/ Abdi Ibrahim","highestDevelopmentStatusID":"9","companyTruncated":"Abdi Ibrahim \/ Abdi Ibrahim"}]

    Find Clinical Drug Pipeline Developments & Deals by Abdi Ibrahim

    Menu

    Abdi Ibrahim

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abdi Ibrahim

                            Turkey arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Abdi Ibrahim

                            Turkey arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPs 7630

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Eskisehir Osmangazi University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option

                            Details : EPs 7630 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hand, Foot and Mouth Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 09, 2024

                            Lead Product(s) : EPs 7630

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Eskisehir Osmangazi University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abdi Ibrahim

                            Turkey arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Abdi Ibrahim

                            Turkey arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AI201901

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients

                            Details : AI201901 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 28, 2021

                            Lead Product(s) : AI201901

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Istanbul Umraniye Training and Research Hospital | Diskapi Yildirim Beyazit Education and Research Hospital | Antalya Training and Research Hospital | Dokuz Eylul University | Ankara City Hospital Bilkent | Kahramanmaras Sutcu Imam University | Uludag Uni

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth